Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Women oncologists participation at the Spanish Society of Medical Oncology (SEOM) annual meetings from 2009 to 2017 and their position in Spanish scientific societies

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Julia Hidalgo Coloma

Citation

Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297

Authors

J. Hidalgo Coloma1, A. Ruiz Hernández2

Author affiliations

  • 1 Medical Oncology, Hospital Lluís Alcanyís, 46800 - Xàtiva/ES
  • 2 Internal Medicine, Hospital Clínico Universitario, 46021 - Valencia/ES
More

Resources

Background

Medical Oncology is a feminized profession in Spain. According to SEOM, 57,6% of the medical oncologists in this country are women. This situation will remain unchanged because women occupied 67% of the medical oncology training positions since 2008. However, women are underrepresented in leadership possitions, which may influence their career development.

Methods

We reviewed the participation, role and gender distribution of 2110 professionals at SEOM annual meetings between 2009-2017, the possition of the 237 members of SEOM executive boards (1976-2017) and the 355 members of the current executive boards of 13 of the most important Spanish cooperative groups.

Results

From 2009 to 2017 the 38,4% of the 2110 speakers at SEOM meetings were women. There wasńt a progressing increase over the years. The only year with >40% of female participation was 2017 (42,4%). At educational and clinical sessions, 26% of chairs and 35% of speakers were women. At original presentations sessions, 57% of presenters, 42% of discusors and 30% of chairs were women. At the plenary sessions, 50% of presenters, 17% of discusors and 5% of chairs were women. 31% of members of scientific committees were women; they chaired these panels in 22% of cases. Over the last decade, SEOM awarded 122 research grants, 42% of them to women. The SEOM executive board has been chaired 18 times by a man and 2 by a woman. The first female president was elected in 2011. There were no women at executive boards until 1987. Women occupied 17,3% of the possitions. Currently, 40% of the executive boards members and 2 of the 13 cooperative groups chairs are women.

Conclusions

Spanish women oncologists developed an active cientific activity in their everyday practice and communicated their research data at national meetings. However they were asked to chair or share their expertise in fewer occasions than men. In addition, women were underrepresented at executive boards of the main oncology scientific groups. According to our results, we consider further efforts are required to achieve gender equality. A good example are initiatives like the ESMO Women for Oncology (W4O) network, the Forum of Women in Oncology in Greece or W4O Italy.

Clinical trial identification

Legal entity responsible for the study

Julia Hidalgo Coloma.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Working arrangements after cancer diagnosis: who, what, when and how?

Presenter: Caroline Alleaume

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)

Presenter: Sebastian Bauer

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings